{"id":"https://openalex.org/W2085029787","doi":"https://doi.org/10.1007/s13300-014-0073-z","title":"The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist","display_name":"The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist","alternate_titles":[],"publication_year":2014,"publication_date":"2014-07-16","ids":{"openalex":"https://openalex.org/W2085029787","doi":"https://doi.org/10.1007/s13300-014-0073-z","mag":"2085029787","pmid":"https://pubmed.ncbi.nlm.nih.gov/25027491","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4269639"},"language":"en","primary_location":{"id":"doi:10.1007/s13300-014-0073-z","doi":"https://doi.org/10.1007/s13300-014-0073-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-014-0073-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0073-z.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2085029787"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0073-z.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080463002","display_name":"Stephen Charles Bain","orcid":"https://orcid.org/0000-0001-8519-4964","observed_orcids":["https://orcid.org/0000-0001-8519-4964"]},"institutions":[{"id":"https://openalex.org/I39586589","display_name":"Swansea University","ror":"https://ror.org/053fq8t95","country_code":"GB","type":"education","lineage":["https://openalex.org/I39586589"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Stephen C. Bain","raw_affiliation_strings":["Institute of Life Science, College of Medicine, Swansea University, Swansea, SA2 8PP, UK, s.c.bain@swansea.ac.uk","Institute of Life Science; College of Medicine; Swansea University; Swansea UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Life Science, College of Medicine, Swansea University, Swansea, SA2 8PP, UK, s.c.bain@swansea.ac.uk","institution_ids":["https://openalex.org/I39586589"]},{"raw_affiliation_string":"Institute of Life Science; College of Medicine; Swansea University; Swansea UK","institution_ids":["https://openalex.org/I39586589"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5080463002"],"corresponding_institution_ids":["https://openalex.org/I39586589"],"apc_list":{"value":7400,"currency":"USD","value_usd":7400},"apc_paid":{"value":7400,"currency":"USD","value_usd":7400},"fwci":1.8777,"has_fulltext":true,"cited_by_count":30,"citation_normalized_percentile":{"value":0.84379274,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"5","issue":"2","first_page":"367","last_page":"383"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":1.0},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8740000128746033},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9129999876022339},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9570000171661377},{"id":"https://openalex.org/keywords/hba1c-reduction","display_name":"HbA1c reduction","score":0.9539999961853027},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.828000009059906},{"id":"https://openalex.org/keywords/gastrointestinal-tolerability","display_name":"gastrointestinal tolerance","score":0.9869999885559082},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.4180000126361847}],"concepts":[{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.9735112190246582},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8469257354736328},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7779804468154907},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.7274973392486572},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.5727970004081726},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.5166125893592834},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4982175827026367},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48731884360313416},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4798147678375244},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4355952739715576},{"id":"https://openalex.org/C3020479747","wikidata":"https://www.wikidata.org/wiki/Q1029907","display_name":"Gastric emptying","level":3,"score":0.4316880702972412},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.4194514751434326},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.36382830142974854},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3349315822124481},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.31948143243789673},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.058976829051971436},{"id":"https://openalex.org/C2779422922","wikidata":"https://www.wikidata.org/wiki/Q1029907","display_name":"Stomach","level":2,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1007/s13300-014-0073-z","doi":"https://doi.org/10.1007/s13300-014-0073-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-014-0073-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0073-z.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4269639","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4269639/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Ther","raw_type":"Text"},{"id":"pmid:25027491","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25027491","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes therapy : research, treatment and education of diabetes and related disorders","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.785.9588","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.785.9588","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/4f/e4/13300_2014_Article_73.PMC4269639.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1007/s13300-014-0073-z","doi":"https://doi.org/10.1007/s13300-014-0073-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-014-0073-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0073-z.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2085029787.pdf","grobid_xml":"https://content.openalex.org/works/W2085029787.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W823783547","https://openalex.org/W1482710124","https://openalex.org/W1584571461","https://openalex.org/W1771491400","https://openalex.org/W1854533075","https://openalex.org/W1967256054","https://openalex.org/W1975929001","https://openalex.org/W2002757015","https://openalex.org/W2003415509","https://openalex.org/W2009288620","https://openalex.org/W2033746319","https://openalex.org/W2045188930","https://openalex.org/W2077751509","https://openalex.org/W2078226063","https://openalex.org/W2095682936","https://openalex.org/W2095774646","https://openalex.org/W2101613382","https://openalex.org/W2106709036","https://openalex.org/W2108122035","https://openalex.org/W2111876001","https://openalex.org/W2129934471","https://openalex.org/W2133648480","https://openalex.org/W2135064706","https://openalex.org/W2154433510","https://openalex.org/W2172193326","https://openalex.org/W4233375494"],"related_works":["https://openalex.org/W2549869317","https://openalex.org/W2108122035","https://openalex.org/W1969897150","https://openalex.org/W2619128140","https://openalex.org/W1533461932","https://openalex.org/W1978569902","https://openalex.org/W2522915330","https://openalex.org/W2031673150","https://openalex.org/W1854533075"],"abstract_inverted_index":{"Lixisenatide":[0,40],"(AVE0010)":[1],"is":[2],"a":[3,45,75,149,234],"once-daily":[4,28,232],"glucagon-like":[5],"peptide-1":[6],"(GLP-1)":[7],"receptor":[8],"agonist":[9,56],"used":[10],"in":[11,44,58,131,140,227],"the":[12,25,32,85,97,135,219],"treatment":[13,186,244],"of":[14,35,47,90,99,184,221],"type":[15,61,102,247],"2":[16,62,103,248],"diabetes.":[17,249],"Phase":[18],"II":[19],"dose-finding":[20],"and":[21,38,68,87,117,177,203,238],"pharmacodynamic":[22],"studies":[23],"identified":[24],"20":[26,92,159],"\u00b5g":[27,93],"dose":[29,237],"as":[30,118],"having":[31],"optimum":[33],"combination":[34],"efficacy,":[36],"convenience":[37],"tolerability.":[39,180,205],"was":[41,163],"prospectively":[42],"investigated":[43],"series":[46],"11":[48],"multinational,":[49],"randomised,":[50],"controlled":[51],"phase":[52],"III":[53],"trials":[54,183],"(GLP-1":[55],"AVE0010":[57],"paTients":[59],"with":[60,79,101,109,134,152,169,173,198,231],"diabetes":[63,228],"mellitus":[64],"for":[65,165,207,246],"Glycemic":[66],"cOntrol":[67],"sAfety":[69],"evaLuation":[70],"[GetGoal]":[71],"programme)":[72],"that":[73],"included":[74],"direct":[76],"head-to-head":[77,150],"study":[78],"exenatide.":[80],"The":[81,125],"GetGoal":[82],"programme":[83],"established":[84],"efficacy":[86,127],"safety":[88],"profile":[89],"lixisenatide":[91,158,185,230],"once":[94,161],"daily":[95,162],"across":[96],"spectrum":[98],"patients":[100,106,172],"diabetes,":[104],"including":[105],"not":[107],"treated":[108],"anti-diabetic":[110],"agents,":[111],"those":[112],"failing":[113],"on":[114],"oral":[115],"agents":[116],"an":[119,242],"adjunct":[120],"to":[121,137,146,188,216],"basal":[122,189],"insulin":[123,190],"therapy.":[124],"main":[126],"endpoints":[128],"were":[129,210],"met":[130],"all":[132],"studies,":[133],"baseline":[136],"endpoint":[138],"reductions":[139,202],"HbA1c":[141,166],"consistently":[142,211],"ranging":[143,213],"from":[144,214],"0.7%":[145],"1.0%.":[147],"In":[148],"comparison":[151],"exenatide":[153],"10":[154],"\u03bcg":[155,160],"twice":[156],"daily,":[157],"non-inferior":[164],"reduction,":[167],"achieved":[168],"threefold":[170],"fewer":[171],"symptomatic":[174],"hypoglycemia":[175],"events":[176,209],"better":[178],"gastrointestinal":[179],"Three":[181],"randomised":[182],"added":[187],"showed":[191],"significantly":[192],"improved":[193],"glycemic":[194],"control":[195],"over":[196],"placebo,":[197],"pronounced":[199],"postprandial":[200],"glucose":[201],"good":[204],"Discontinuations":[206],"adverse":[208],"low,":[212],"2.5%":[215],"10.4%.":[217],"As":[218],"provision":[220],"individualized":[222],"care":[223],"moves":[224],"center":[225],"stage":[226],"management,":[229],"dosing,":[233],"single":[235],"maintenance":[236],"fixed-dose":[239],"pens":[240],"offers":[241],"important":[243],"option":[245]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2085029787","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
